We show you our most important and recent visitors news details US approves Roche's drug Actemra for emergency use against severe COVID-19 in the following article
Hind Al Soulia - Riyadh - WASHINGTON — The US Food and Drug Administration has issued an emergency use authorization for the drug Actemra for the treatment of hospitalized COVID-19 adults and pediatric patients.
The authorization was issued on Thursday to Genentech, a subsidiary of Roche Holding AG.
The drug can be used to treat patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
The FDA also said that Actemra helped reduce risk of death and speed recovery citing scientific studies.
The EUA is based on results from four randomized, controlled studies that evaluated Actemra for the treatment of COVID-19 in more than 5,500 hospitalized patients, Roche said.
“Even with the availability of vaccines and declines in deaths from COVID-19 in various parts of the world, we continue to see new hospitalizations from severe forms of the disease,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development.
“We are pleased that Actemra/RoActemra is now authorized as an option that may help improve outcomes for adults and children hospitalized with COVID-19 in the United States.” — Agencies
These were the details of the news US approves Roche's drug Actemra for emergency use against severe COVID-19 for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Saudi Gazette and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.